

01

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 1 577 289 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:  
21.09.2005 Bulletin 2005/38

(51) Int Cl.7: C07C 233/00, C07C 237/00

(21) Application number: 04006461.0

(22) Date of filing: 18.03.2004

(84) Designated Contracting States:  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HU IE IT LI LU MC NL PL PT RO SE SI SK TR  
Designated Extension States:  
AL LT LV MK

• Aydt, Ewald Mirko, Dr.  
10247 Berlin (DE)



(74) Representative: Huhn, Michael et al  
Isenbruck Bösl Hörschler  
Wichmann Huhn  
Patentanwälte  
Theodor-Heuss-Anlage 12  
68165 Mannheim (DE)

(71) Applicant: Revotar Biopharmaceuticals AG  
16761 Henningsdorf (DE)

(72) Inventors:  
• Kranich, Remo, Dr.  
13503 Berlin (DE)


(54) Non-glycosylated/-glycosidic/-peptidic small molecule selectin inhibitors for the treatment of inflammatory disorders

(57) The compounds having the general structure of formula (I)




with R<sup>4</sup> being H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>


or



or



and Y being



wherein the symbols, indices and substituents have the following meaning

if R<sup>2</sup>=OH and R<sup>3</sup>=H then R<sup>1</sup>=H, CN, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, CH<sub>3</sub> or


if R<sup>3</sup>=OH and R<sup>2</sup>=H then R<sup>1</sup>=H, CN, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, CH<sub>3</sub>, Et, n-Pr, i-Pr, n-Bu, i-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl or

if R<sup>3</sup>=OH and R<sup>1</sup>=H then R<sup>2</sup>=H, CN, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, CH<sub>3</sub>, Et, n-Pr, i-Pr,


n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl  
then X is e.g.

EP 1 577 289 A1

EP 1 577 289 A1



or



and the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formula (I). The compounds are applied to modulate the in-vitro and in-vivo binding processes mediated by E-, P- or L-selectin binding.


## Description

[0001] Compounds and methods are provided, which modulate the in-vitro and in-vivo binding processes mediated by E-selectin, P-selectin or L-selectin binding. More specifically, selectin inhibitors and their use are described, wherein the selectin inhibitors that inhibit the selectin-mediated function comprise polyhydroxy phenyl subunits.

[0002] When a tissue has been invaded by a microorganism/is infected or has been damaged, the inflammatory process directs leukocytes and other immune system components to the site of infection or injury. Within this process, leukocytes (white blood cells) play a major role in the engulfment or digestion of microorganisms. Thus, the recruitment of leukocytes to infected or damaged tissue is critical for mounting an effective immune defense. Generally, white blood cells are found circulating through the bloodstream. To migrate from the blood stream into the affected tissue, the white blood cells must be able to recognize the invaded or damaged tissue and be able to bind to the wall of the capillary (endothelium) near the affected tissue and diffuse through the capillary into the affected tissue. Therefore, leukocytes have to roll and adhere to the endothelial cell wall. This cell adhesion event is one of the most important aspects of the inflammatory response. The first steps of this cell adhesion are mediated by members of the selectin family. The selectin family of vascular adhesion molecules is comprised of three structurally related calcium-dependent carbohydrate binding cell surface proteins, P-, L- and E-selectin. E-selectin is expressed only on inflamed endothelium, P-selectin is expressed on inflamed endothelium as well as on platelets, and has much structural similarity to E-selectin. L-selectin is expressed on leukocytes and also has much structure similarity to P- and E-selectins. The selectins are transmembrane proteins and are composed of an amino terminal lectin domain, an epidermal growth factor (EGF)-like domain, a variable number of complement receptor-related repeats, a hydrophobic domain spanning region and a cytoplasmic domain. The binding interactions which lead to the adhesion of the leukocytes appear to be mediated by contact of the lectin domain of the selectins and various carbohydrate ligands on the surface of the leukocytes. All three selectins can bind to the carbohydrate sialyl Lewis<sup>x</sup>, a glycosyl moiety present on the surface of most/certain leukocytes. In case of P- and L-selectin, a distinct protein ligand has been described [R.P. McEver; R.D. Cummings; *J. Clin. Invest.*; 1997; 100; 485-492], the so-called PSGL-1 (P-selectin glycoprotein ligand-1), which contributes to a high affinity selectin binding by its sLe<sup>x</sup> moiety as well as by parts of its peptide components, sulphated tyrosine [R.P. McEver; *Ernst Schering Res. Found. Workshop*; 2004; 44; 137-147]. PSGL-1 is one of the most important selectin ligands binding with highest affinity to P-selectin, but it also binds to E- and L-selectin. It is expressed as homodimeric sialomucin on leukocytes and platelets where it is upregulated during inflammation.

[0003] In contrast to their low basal expression, E- and P-selectin expression is also upregulated during inflammation, leading to a substantial recruitment of leukocytes into the inflamed tissue. Although selectin-mediated cell adhesion is required for fighting infection, there are situations in which such cell adhesion is undesirable or excessive, resulting in tissue damage instead of repair. In the case of many acute as well as chronic inflammatory disorders (e.g., asthma, chronic obstructive pulmonary disease (COPD), psoriasis, etc.) an association between infiltration of activated leukocytes into the tissue simultaneously with a marked elevation of tissue expression of corresponding adhesion molecules, particularly E- and P-selectin, has been demonstrated. Such abnormal white blood cell infiltration, caused by extensive selectin expression may also play a role in transplant and graft rejection. Also the process of blood clotting is further promoted by leukocyte-leukocyte and leukocyte-platelet binding, which occurs because leukocytes possess as well L-selectin as its corresponding ligand PSGL-1 and can thus interact with themselves, via PSGL-1, and they can also bind to platelets which carry P-selectin.

[0004] D. Bock et al., *New Drugs*, p. 28 to 30 (28.04.2003) describe the role of selectin antagonists, especially bi-mosiamose, as inhibitor of selectins being an inflammation target:



[0005] As additional targets MIF (Macrophage Migration Inhibitory Factor) and JAM-1 (Junctional Adhesion Molecule 1) are mentioned.


[0006] EP 0 758 243 B1 describes Mannopyranosyloxy-phenyl-benzoic acid or similar acids as components in a medicine for treating or preventing diseases, characterized by the binding of E-, P- and/or L-selectin to a sialyl-Lewis x (sLe<sup>x</sup>) or sialyl-Lewis a (sLe<sup>a</sup>) presented on a cell surface through the inhibition of such binding. Besides inflammatory diseases, other diseases like septic shock, psoriasis, rheumatoid arthritis, reperfusion injury and cancer are mentioned.

[0007] From EP 0 840 606 B1 compounds like bimosiamose are known, e.g., 1,6-Bis-[3-(carboxymethylphenyl)-4-(2- $\alpha$ -D-mannopyranosyloxy)phenyl]hexan and derivatives thereof including heptan, butan and pentan derivatives. Again, their use for inhibiting the selectin binding to sLe<sup>x</sup> or sLe<sup>a</sup> are mentioned.


[0008] A different method for inhibiting the binding between a first cell having a selectin and a second cell having a ligand for selectin in vitro is described in EP 0 902 681 B1 in permitting a lipid composition to interact with the first cell. A proportion of the lipids has an attached saccharide like fucooligosaccharides or lactose, a different proportion has, e.g., a second attached acidic monosaccharide, further proportions are crosslinked and a proportion without attached saccharides have an acidic group being negatively charged at neutral pH. These lipid compositions are used in local alterations in the adherence of leukocytes or cancer cells to vascular endothelium, platelets or lymphatic tissue.

[0009] EP 1 288 222 A1 describes compounds with affinity to P-selectin being peptides with a specific amino acid sequence comprising, e.g., valine, tryptophan, aspartic acid, and D- or L-glutamic acid. Medicaments comprising these peptides are said as inhibiting leukocyte binding to platelets and/or endothelial cells. Similar peptides are known from WO-A 03/020753.

[0010] The disalicylates and disalicylate-based C-glycosides of WO-A 99/29706 act as selectin-ligand structural mimetics in medicaments. They may lack the sialic acid and/or fucose of the natural selectin ligand being sLe<sup>x</sup>. A typical compound is




[0011] The 5-membered heterocycles of WO-A 00/33836 exhibit inhibitory activity against the selectins; typical structures are





with substituents like a moiety containing a terminal carboxylic acid group as a non-N substituent, a hydrophobic moiety such as a functionalized alkyl chain as a non-N substituent and a functionalized aryl group which also may be an N-substituent.

[0012] WO-A 01/89531 provides methods for identifying agents which interact with (activate or inhibit) the crystal and three-dimensional structures of a) the lectin and EGF-like (LE) domains of P-selectin, of b) P-selectin LE and E-selectin LE each complexed with sLe<sup>x</sup>, and c) P-selectin LE complexed with a functional PSGL-1 peptide modified by both tyrosine sulfation and sLe<sup>x</sup>.

[0013] The compounds for modulating in vitro and in vivo processes mediated by selectin binding according to WO-A 03/097658 are benzyl amino sulfonic acids linked to carbohydrate or glycomimetic. A typical compound would be



C.C.M.Appeldoorn et al. in JPC Papers in Press, published January 13, 2003, with the title "Optimization of a P-selectin binding peptide" report on peptides containing a Glu-Trp-Val-Asp-Val consensus motif to which gallic acid or 1,3,5-benzenetricarboxylic acid at the N-terminus have been added as substituents. C-terminus modifications had little to no influence on the affinity of the core peptide. The two typical substituents are




is a typical peptide rest.

**[0014]** In such a very complex pharmaceutical field, there is a strong medical need in the art for indentifying further inhibitors of selectin-mediated function. e.g. of selectin-dependent cell adhesion, and for the development of methods employing such compounds to inhibit conditions associated with excessive selectin activity. Most of the available pharmaceutical therapies e.g. of psoriasis or asthma, which are available on the market comprise mostly corticosteroids or NSAIDs (non steroidal anti-inflammatory drugs) which have several serious drawbacks/side effects, and target different steps of the inflammatory cascade.

**[0015]** Object of the invention is to provide new compounds, especially non-glycosylated/glycosidic relatively small molecules, which are able to inhibit selectin and which have less negative side effects during their in-vitro or in-vivo application. Furthermore, the said molecules should show a good bioavailability when applied as an active ingredient in a medicine.

**[0016]** The present invention provides compounds having the general structure of formula (I).





wherein the symbols, indices and substituents have the following meaning

if  $R^2=OH$  and  $R^3=H$  then  $R^1=H, CN, NO_2, CF_3, F, Cl, Br, I, CH_3$  or

if  $R^3=OH$  and  $R^2=H$  then  $R^1=H, CN, NO_2, CF_3, F, Cl, Br, I, CH_3, Et, n-Pr, i-Pr, n-Bu, i-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl$  or




if  $R^3=OH$  and  $R^1=H$  then  $R^2=H, CN, NO_2, CF_3, F, Cl, Br, I, CH_3, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl$   
 $-X-$  =

(a)








with  $-E-$  being  $-NH-$ ,  $-(CH_2)_kNH-$ ;  $-G-$  being  $-(NH)_m$  and  $g = 0,1$ ;  $h = 1, 2, 3$ ;  $k = 1, 2, 3$ ;  $m = 0,1$ ;  $n =$  an integer from 1 to 8

(b)




with  $R^4$  being  $H, CH_3, CH_2CH_3$

(c)






with  $R^5$  being H,  $NO_2$ ,  $CF_3$ , F, Cl, Br, I, CN,  $CH_3$  and -K- being -S- or -O-

(d)






with p being an integer from 2 to 8

(e)




with q being an integer from 1 to 9 and r being an integer from 1 to 3








(f)



with -T<sup>1</sup>-, -T<sup>2</sup>-being -E-, -K- or -(N-alkyl)--Y =







with -V- being -(NH-)<sub>s</sub> - with s being 0 or 1,

[0017] R<sup>6</sup> being CO<sub>2</sub>H, CO<sub>2</sub>Alkyl, CO<sub>2</sub>Aryl, CO<sub>2</sub>NH<sub>2</sub>, CO<sub>2</sub>Aralkyl, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, PO(OH)<sub>2</sub>, 1-H-tetrazolyl-, CHO, COCH<sub>3</sub>, CH<sub>2</sub>OH, NH<sub>2</sub>, NHAalkyl, N(Alkyl)Alkyl, OCH<sub>3</sub>, CH<sub>2</sub>OCH<sub>3</sub>, SH





R<sup>7</sup> independently from R<sup>6</sup> being H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, NO<sub>2</sub> and

R<sup>8</sup> independently from R<sup>6</sup> and R<sup>7</sup> being H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, NO<sub>2</sub>, R<sup>6</sup>



R<sup>9</sup> being H, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, CH<sub>3</sub>, OCH<sub>3</sub>, SH

t being 0,1,2



and -W- = -(CH<sub>2</sub>)<sub>v</sub>, *cis*-CH=CH- or *trans*-CH=CH-, and v being 0,1,2 -Z =



[0018] Preferred compounds are those of formulas (A) and (B)





wherein -Y is (Q=CH, N)




with R<sup>10</sup> being CO<sub>2</sub>H, CO<sub>2</sub>alkyl, CO<sub>2</sub>aryl, CO<sub>2</sub>NH<sub>2</sub>, CO<sub>2</sub>aralkyl, CH<sub>2</sub>SO<sub>3</sub>H, CH<sub>2</sub>SO<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>PO(OH)<sub>2</sub>, 1-H-tetrazolyl, CHO, COCH<sub>3</sub>, CH<sub>2</sub>OH, CH<sub>2</sub>NH<sub>2</sub>, CH<sub>2</sub>NHalkyl, CH<sub>2</sub>N(alkyl)alkyl', CH<sub>2</sub>OCH<sub>3</sub>, CH<sub>2</sub>SH.

R<sup>11</sup> being CO<sub>2</sub>H, CO<sub>2</sub>alkyl, CO<sub>2</sub>aryl, CO<sub>2</sub>NH<sub>2</sub>, CO<sub>2</sub>aralkyl, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, PO(OH)<sub>2</sub>, 1-H-tetrazolyl, CHO, COCH<sub>3</sub>, OH, NH<sub>2</sub>, NHalkyl, N(alkyl)alkyl, OCH<sub>3</sub>, SH

[0019] Further particularly preferred compounds include the following formulas (C) and (D)



wherein Y is like relating to formulas (A) and (B) and X is:



[0020] Also part of the invention are the pharmaceutically acceptable salts, esters or amides and prodrugs of the above-identified compounds of formula (I).

The present invention also provides pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine. These compounds present the ability of inhibiting cell adhesion and inhibit selectin-[as well as PSGL-1-mediated] binding. The compounds have the ability to inhibit the interaction of selectins with sLe<sup>x</sup> / sLe<sup>a</sup> and also the interaction between selectins and tyrosinesulfate residues.

In a preferred variant the invention provides pharmaceutical compositions comprising at least one compound of formula (A) or formula (B) or formula (C) or formula (D) and a pharmaceutically acceptable carrier. The present invention further provides a method of inhibiting the binding of P-selectin, L-selectin or E-selectin to sLe<sup>x</sup> or sLe<sup>a</sup> and tyrosinesulfate residues comprising the step of administering to a patient an effective amount of at least one compound having the structure of formula (I) to inhibit the binding of P-, E- or L-selectin to sLe<sup>x</sup> or sLe<sup>a</sup> and tyrosinesulfate.

[0021] It has been found that compounds having the formula (I) shown above act to inhibit E, P, or L-selectin binding. As used herein the term "alkyl" shall mean a monovalent straight chain or branched chain group of 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 carbon atoms including, but not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl and the like.

The term "aryl" shall mean carbocyclic and heterocyclic aromatic groups including, but not limited to, phenyl, 1-naphthyl, 2-naphthyl, fluorenyl, (1,2)-dihydronaphthyl, indenyl, indanyl, thienyl, benzothienyl, thienopyridyl and the like.

The term "aralkyl" (also called arylalkyl) shall mean an aryl group appended to an alkyl group including, but not limited to, benzyl, 1-naphthylmethyl, 2-naphthylmethyl, fluorobenzyl, chlorobenzyl, bromobenzyl, iodobenzyl, alkoxybenzyl (wherein "alkoxy" means methoxy, ethoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy and the like), hydroxybenzyl, aminobenzyl, nitrobenzyl, guanidinobenzyl, fluorenylmethyl, phenylmethyl(benzyl), 1-phenylethyl, 2-phenylethyl, 1-naphthylethyl and the like.

[0022] The term "pharmaceutically acceptable salts, esters, amides and prodrugs" as used herein refers to those carboxylate salts, amino acid addition salts, esters, amides and prodrugs of the compounds of the present invention which are, within the scope of sound medical judgement, suitable for use in contact with tissues of patients without undue toxicity, irritation, allergic response and the like, commensurate with a reasonable benefit/risk ratio, and effective

for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention. The term "salts" refers to the relatively non-toxic, inorganic and organic acid addition salts of the compounds of the present invention. These salts can be prepared *in situ* during the final isolation and purification of the compounds or by separately reacting the purified compounds in its free form with a suitable inorganic or organic acid or base and isolating the salt thus formed. Representative salts of the compounds of the present invention include the hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulphonate salts and the like. These may include cations based on the alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium and the like, as well as non-toxic ammonium, quaternary ammonium and amine cations including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, and the like.

Examples of the pharmaceutically acceptable, non-toxic esters of the compounds of this invention include C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub> and C<sub>6</sub> alkyl esters wherein the alkyl group is a straight or branched chain. Acceptable esters also include C<sub>5</sub>, C<sub>6</sub> and C<sub>7</sub> cycloalkyl esters as well arylalkyl esters such as, but not limited to benzyl. C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub> and C<sub>6</sub> alkyl ester are preferred. Esters of the compounds of the present invention may be prepared according to conventional methods.

[0023] Examples of pharmaceutically acceptable, non-toxic amides of compounds of this invention include amides derived from ammonia, primary C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub> and C<sub>6</sub> alkyl amines and secondary C<sub>1</sub>, C<sub>2</sub>, C<sub>3</sub>, C<sub>4</sub>, C<sub>5</sub> and C<sub>6</sub> dialkyl amines wherein the alkyl groups are straight or branched chains. In the case of secondary amines the amine may also be in the form of a 5 or 6 membered heterocycle containing one nitrogen atom. Amides derived from ammonia, C<sub>1</sub>, C<sub>2</sub> and C<sub>3</sub> alkyl primary amides and C<sub>1</sub> to C<sub>2</sub> dialkyl secondary amides are preferred. Amides of the compounds of the present invention may be prepared according to conventional methods.

[0024] The term "prodrug" refers to one or more compounds that are rapidly transformed *in vitro* and from a non-active to active state *in vivo* to yield to the parent compound of the above formula (I), for example by hydrolysis in blood or *in vivo* metabolism.

The present invention also provides for pharmaceutically active compositions that contain the compounds of the present invention. It is also contemplated that pharmaceutically active compositions may contain a compound of the present invention or other compounds that inhibit or compete with E-selectin or P-selectin or L-selectin binding.

Pharmaceutically active compositions of the present invention comprise a physiological carrier and a compound of formula (I). The pharmaceutical compositions of the present invention may include one or more of the compounds having the above structure (I) formulated together with one or more non-toxic, physiologically acceptable carriers, adjuvants or vehicles, which are collectively referred to herein as carriers, for parenteral injection, for oral administration in solid or liquid form, for rectal or topical administration and the like.

The compositions can be administered to humans and animals either orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), intracisternally, intravaginally, interperitoneally, locally (powders, ointments or drops), or as a buccal or by inhalation (nebulized, or as nasal sprays).

Compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or non-aqueous solutions, dispersion, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solution or dispersion. Examples of suitable aqueous and nonaqueous carriers, diluents, solvents or vehicles include water, ethanol, polyol, (propylene glycol, polyethylene glycol, glycerol and the like), suitable mixtures thereof, vegetable oils (such as olive or canola oil) and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for examples, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.

These compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. Prevention of the actions of microorganisms can be ensured by various antibacterial and antifungal agents, for examples, parabens, chlorobutanol, phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, for examples sugars, sodium chloride and the like. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, for examples aluminium monostearate and gelatin.

If desired, and for more effective distribution, the compounds can be incorporated into slow or timed release or targeted delivery systems such as polymer matrices, liposomes, and microspheres. They may be sterilized, for example, by filtration through a bacteria-retaining filter, or by incorporating sterilizing agents in the form of sterile water, or some other sterile injectable medium immediately before use.

Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules. In such solid dosage forms, the active compound or a prodrug ester is admixed with at least one inert customary excipient (or carrier) such as sodium citrate or dicalcium phosphate or (i) fillers or extenders, as for example, starches, lactose, sucrose, glucose, mannitol and silicic acid, (ii) binders, as for example, carboxymethylcellulose, alginates, gelatine, polyvinylpyrrolidone, sucrose and acacia, (iii) humectants, as for example, glycerol, (div disintegrating agents, as for example, agar-agar, calcium carbonate, potato or tapioca starch, aliginic acid, certain complex silicates and sodium carbonate,

(v) solution retarders, as for examples, paraffin, (vi) absorption accelerators, as for example, quaternary ammonium compounds, (vii) wetting agents, as for examples, cetyl alcohol and glycerol monostearate, (viii) adsorbents, as for example, kaolin and bentonite, and (ix) lubricants, as for example, talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate and mixtures thereof. In the case of capsules, tablets, and pills, the dosage forms may also comprise buffering agents.

Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatine capsules using excipients as lactose or milk sugars as well as high molecular polyethylene glycols and the like.

Solid dosage forms such as tablets, dragées, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and others well known in the art. They may contain opacifying agents, and can also be of such compositions that they release the active compound or compounds in a certain part of the intestinal tract in a delayed manner. Examples of embedding compositions that can be used are polymeric substances and waxes.

The active compounds can also be in microencapsulated form, if appropriate, with one or more of the above-mentioned excipients.

Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as water or other solvents, solubilizing agents and emulsifiers, as for example, ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils, in particular, cottonseed oil, groundnut oil, corn germ oil, olive oil, canola oil, castor oil and sesame seed oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan or mixtures of these substances, and the like.

Besides such inert diluents, the compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavouring and perfuming agents.

Suspensions, in addition to the active compounds, may contain suspending agents, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminium metahydroxide, bentonite, agar-agar, tragacanth or mixtures of these substances and the like.

Compositions for rectal administrations are preferably suppositories, which can be prepared by mixing the compounds of the present invention with suitable nonirritating excipients or carriers such as cacao butter, polyethylene glycol or a suppository wax, which are solid at ordinary temperatures but liquid at body temperature and therefore melt in the rectal or vaginal cavity and release the active component.

Dosage forms for topical administration of a compound of this invention include ointments, powder, sprays and inhalants.

The active component is admixed under sterile conditions with a physiologically acceptable carrier and any needed preservatives, buffers or propellants as may be required. Ophthalmic formulations, eye ointments, suspensions, powder and solutions are also contemplated as being within the scope of this invention.

The compounds of the present invention can also be administered in the form of liposomes. As is known in the art, liposomes are generally derived from phospholipids or other lipid substances. Liposomes are formed by mono or multilamellar hydrated liquid crystals that are dispersed in an aqueous medium. Any non-toxic, physiologically acceptable metabolized lipid capable of forming liposomes can be used. The present compositions in liposome form can contain, in addition to the selectin binding inhibitors of the present invention, stabilizers, preservatives, excipients and the like. The preferred lipids are the phospholipids and the phosphatidyl cholines (lecithins), both natural and synthetic. Methods to form liposomes are well known in the art.


Actual dosage levels of active ingredient in the composition of the present invention may be varied so as to obtain an amount of active ingredient that is effective to obtain the desired therapeutic response for a particular composition and method of administration. The selected dosage level, therefore, depends on the desired therapeutic effect, on the route of administration, on the desired duration of treatment and other factors.

The total daily dosage of the compounds on this invention administered to a host in single or divided doses may be in the range up to 50 mg per kilogram of body weight. Dosage unit compositions may contain such submultiples thereof as may be used to make up the daily dosage. It will be understood, however, that the specific dose level for any particular patient, whether human or other animal, will depend upon a variety of factors including the body weight, general health, sex diet, time and route of administration, rates of absorption and excretion, combination with other drugs and the severity of the particular disease being treated.

In particular, the compounds of the present invention may be used to treat a variety of diseases relating to inflammation and cell-cell recognition and adhesion. For example, the compounds of the present invention may be administered to a patient to treat COPD, acute respiratory distress syndrome (ARDS), Crohn's disease, septic shock, chronic inflammatory diseases such as psoriasis, atopic dermatitis, and rheumatoid arthritis, and reperfusion tissue injury that occurs following heart attacks, strokes, atherosclerosis, and organ transplants, traumatic shock, multi-organ failure, autoimmune diseases like multiple sclerosis, asthma and inflammatory bowel disease. In each case, an effective amount of the compounds of the present invention is administered either alone or as part of a pharmaceutically active




## SCHEME 2




In SCHEME 2 a carboxy substituted thiophene like (5) is reacted to the corresponding ethyl ester (6) under heating in acidic ethanol. Ester (6) is brominated with N-bromosuccinimide in anhydrous chloroform and glacial acetic acid to give (7) which is further reacted with 2-Amino-benzeneboronic acid under a state-of-the-art Suzuki transformation (i. e. Tetrakis(triphenylphosphine)-palladium, aqueous sodium carbonate, ethanol, toluene) to the biaryl (8). Biaryl (8) is reacted with a trimethoxy-phenyl-alkyl acid, EDC, triethylamine and DMAP in a chlorinated solvent to the amide (9). Alternatively DIC and HOBt may be used for this reaction step. Amide (9) is converted to acid (10) by treating it with an excess of boron tribromide at -78°C up to rt in a halogenated solvent followed by aqueous workup. However, in some cases it may be necessary to hydrolyze the ester (9) with i. e. aqueous lithium hydroxide in acetonitrile before treating it with boron tribromide.

## SCHEME 3



In SCHEME 3 4-Amino-butyric acid hydrochloride (11) is reacted at rt with an trimethoxybenzoic acid under basic conditions (triethylamine in anhydrous dichloromethane) to the amide (12) which is further hydrolyzed with aqueous lithium hydroxide in acetonitrile to give a building block like (13).

## SCHEME 4




In SCHEME 4 an acid like (13) is reacted with an aniline of general type (14) under state-of-the-art conditions (i.e. EDC, triethylamine and DMAP in a chlorinated solvent) to form the amide (15). Alternatively DIC and HOBt may be used for this reaction step. Amide (15) is converted to acid (16) by treating it with an excess of boron tribromide at  $-78^\circ\text{C}$  up to rt in a halogenated solvent followed by aqueous workup.

In case that  $\text{R}^6$  and/or  $\text{R}^8$  contain carboxylic acid functionalities, those are protected as their corresponding methyl or ethyl esters before and hydrolyzed afterwards to release the carboxylic acid functionalities. The ester hydrolysis was done whether with  $\text{LiOH}$  in MeCN or under treatment with  $\text{BBR}_3$  in followed by addition of water.

The synthesis sequence shown in SCHEME 4 leading to compounds like (16) is not only reduced to X-Y-H and Y-H building blocks like (14) but may be generally applied to all other X-Y-H and Y-H type building blocks leading to compounds of type (C) and (D) as shown in the paragraphs before.



## SCHEME 5



For compounds of type (23) containing a carboxylic acid functionality a synthesis sequence according to SCHEME 5 may be applied. An aniline of type (17) is reacted at rt with 9-fluorenylmethoxycarbonyl chloride (Fmoc-Cl) in 1,4-dioxane and aqueous sodium carbonate to the corresponding Fmoc-protected compound (18). Acid (18) is immobilized on solid support by esterification with 2-Chlorotriylchloride-polystyrene and Huenig's base in anhydrous dichloromethane and N,N-dimethylformamide at rt to give (19) which is further treated with piperidine in N,N-dimethylformamide. The resulting compound (20) is reacted then with acid (13), DIC and HOBT in N,N-dimethylformamide at rt. The resulting amide (21) is treated with 1,1,1,3,3,3-Hexafluoro-2-propanol in dichloromethane at rt to cleave (22) from solid support. Following treatment of (22) with an excess of boron tribromide in dichloromethane at -78°C up to rt and aqueous workup provides the desired compound (23).


The present invention is furthermore illustrated by the following representative examples.

## EXAMPLE 1

{3-[3-(2,3,4-Trihydroxy-phenyl)-propionylamino]-phenyl}-acetic acid (27)

[0026]

## SCHEME 6



[0027] Step 1: Dissolve (3-Amino-phenyl)-acetic acid ((24), 700mg, 4.63mmol) in MeOH (21mL) and add conc. sulfuric acid (0.27mL, 5.09mmol). Stir the reaction mixture for 2d under reflux. Cooled mixture to room temperature (rt), remove solvent under reduced pressure and prepurify the residue by flushing it over a short pad of silica gel using EtOAc. Remove solvent again and partition the residue between EtOAc and saturated aq. NaHCO<sub>3</sub> (1+1). Extract the aqueous layer 3 times with EtOAc, wash the combined organic layers with brine and dried with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure and dry the residue without further purification in oil pump vacuum to obtain product (25) as a light yellow oil (708mg, 92%). <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 3.51 (s, 2 H); 3.67 (s, 3 H); 6.57 (dd, 1 H, J<sub>1</sub> = 7.8Hz, J<sub>2</sub> = 1.8Hz); 6.60 (br. t, 1 H, J = 1.8Hz); 6.65 (br. d, 1 H, J = 7.8Hz); 7.08 (t, 1 H, J = 7.8Hz).

[0028] Step 2: (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.) Dissolve EDC hydrochloride (187mg, 0.98mmol) and triethylamine (0.14mL, 1.00mmol) in anhydrous dichloromethane (3.5mL) and stir for 5min at rt. Added 3-(2,3,4-Trimethoxy-phenyl)-propionic acid (234mg, 0.97mmol) and DMAP (12mg, 0.10mmol) and stir for 10min. Added ester (25) (107mg, 0.65mmol) and stir the reaction solution overnight at rt.

Hydrolyze the reaction solution with saturated aq. NH<sub>4</sub>Cl followed by water, separate layers, extract aq. layer with dichloromethane (3 times) and wash the combined organic layers with water and brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure.

Purify crude product by preparative radial chromatography (silica gel 60PF, EtOAc/CyH 1+1) to obtain product (26) as a white solid (209mg, 83%). [K. C. Nicolaou; P. S. Baran; Y.-L. Zhong; K. Sugita; *J. Am. Chem. Soc.*; 2002; 124; 10; 2212-2220]. <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 2.62 (t, 2 H, J = 7.5Hz); 2.95 (t, 2 H, J = 7.5Hz); 3.58 (s, 2 H); 3.67 (s, 3 H); 3.82 (s, 3 H); 3.84 (s, 3 H); 3.91 (s, 3 H); 6.59 (d, 1 H, J = 8.6Hz); 6.86 (d, 1 H, J = 8.6Hz); 6.98 (br. d, 1 H, J = 7.8Hz); 7.32 (t, 1 H, J = 7.8Hz); 7.38 (br. d, 1 H, J = 7.8Hz); 7.41 (br. s, 1 H).

[0029] Step 3: (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.) Dissolve (26) (139mg, 0.36) in anhydrous dichloromethane (1.8mL), cooled to -78°C (acetone/ dry ice bath) and add slowly BBr<sub>3</sub> (0.51mL, 5.39mmol). Stir the reaction mixture for additional 30min at -78°C. Remove cooling bath and stir the reaction mixture for 3h at rt. Cool reaction mixture to 0°C, add slowly water (0.50mL) under vigorous stirring followed by dichloromethane (1.0mL) and methanol (2.0mL). Extract the mixture with EtOAc (3 times) and dry the combined organic layers with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure and purify crude product by preparative RP HPLC (gradient, water/MeCN


95:5) to obtain {3-[3-(2,3,4-Trihydroxy-phenyl)-propionylamino]-phenyl}-acetic acid (27) as a white solid (69mg, 57%).  
 [T. P. Kogan; B. Dupré; H. Bui; K. L. McAbee; J. M. Kassir; I. L. Scott; X. Hu; P. Vanderslice; P. J. Beck; R. A. F. Dixon. *J. Med. Chem.*, 1998; 41; 1099-1111]. <sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD): 2.67 (t, 2 H, J = 7.6Hz); 2.92 (t, 2 H, J = 7.6Hz); 3.61 (s, 2 H); 6.31 (d, 1 H, J = 8.3Hz); 6.50 (d, 1 H, J = 8.3Hz); 7.05 (br.d, 1 H, J = 7.8Hz); 7.28 (Ψt, 1 H, J = 7.8Hz); 7.48 (br.d, 1 H, J = 7.8Hz); 7.49 (br.s, 1 H).

## EXAMPLE 2

(5-[2-[2-(2,3,4-Trihydroxyphenyl)-acetyl-amino]-phenyl]-thiophen-2-yl)acetic acid (34)

[0030]

## SCHEME 7



[0031] **Step 1:** Dissolve Thiophene-2-yl-acetic acid (28) (2.44g, 17.1mmol) in ethanol (35mL) and add fuming aqu. hydrochloric acid (few drops). Stir the reaction mixture for 19h at 70 °C. Cool mixture to rt, remove solvent under reduced pressure and resolve the residue in EtOAc. Wash this organic layer 3 times with 5% aqu. Na<sub>2</sub>CO<sub>3</sub> and extract the combined aqueous layer 3 times with EtOAc. Wash the combined organic layers with brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Remove solvent under reduced pressure and dry the residue without further purification in oil pump vacuum to obtain product (29) as a light brown oil (2.78g, 95%). [J. Kunes; V. Balsanek; M. Pour; V. Buchta; *Collect. Czech. Chem. Commun.*, 2001, 66; 12; 1809-1830]. <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 1.26 (t, 3 H, J = 7.1 Hz); 3.81 (s, 2 H); 4.17 (q, 2 H,

$J = 7.1$  Hz); 6.91-6.96 (m, 2 H); 7.20 (d, 1 H,  $J = 4.8$  Hz).

[0032] Step 2: (The following reaction is done in an anhydrous  $N_2$  atmosphere.) Dissolve ester (29) (1.30g, 7.64mmol) in anhydrous chloroform (6.0mL) and glacial acetic acid (6.0mL), add N-Bromosuccinimide (1.39g, 7.79mmol) in portions and stir the mixture for 23h at rt. The mixture is diluted with an equal volume of water, the organic layer separated and washed with a 1M aq. NaOH, water, again with 1M aq. NaOH and water (2 times). Finally wash the organic layer with brine and dry with  $Na_2SO_4$ . Remove solvent under reduced pressure. Purify crude product by preparative radial chromatography (silica gel 60PF, CyH/EtOAc 5+1) to obtain product (30) as an impure (according to NMR: 20% sideproduct) orange liquid (1.61g, 85%) which is used without any further purification. [P. M. Jackson; C. J. Moody; P. Sha; J. *Chem. Soc. Perkin Trans. 1*; 1990; 2909-2918].  $^1H$  NMR (400MHz,  $CDCl_3$ ): 1.26 (t, 3 H,  $J = 7.1$  Hz), 3.73 (s, 2 H); 4.17 (q, 2 H,  $J = 7.1$  Hz); 6.67 (d, 1 H,  $J = 3.5$  Hz); 6.88 (d, 1 H,  $J = 3.5$  Hz).

[0033] Step 3: (The following reaction is done in an oxygen-free  $N_2$  atmosphere.) ethanol (1.47mL), Tetrakis-(triphenylphosphine)-palladium(0) (59.0mg, 2.5mol%) and aq.  $Na_2CO_3$  (1.60g, 5.60mmol; presolved in 2.0mL  $H_2O$ ) are subsequently added to dissolved 2-Aminobenzenboronic acid (341mg, 2.20 mmol) in toluene (16mL). The reaction mixture is degassed 5 times and flooded with  $N_2$  again. Add bromide (30) (498mg, 2.00mmol) and rinse with toluene (4.5 mL), degas again (5 times) and stir the reaction solution 21h at 100°C. Partition the reaction solution between EtOAc and brine (1+1) and extract the separated aqueous layer 3 times with EtOAc. Wash combined organic layer with brine and dry with  $Na_2SO_4$ . Remove solvent under reduced pressure and purify the crude product by preparative radial chromatography (silica gel 60PF, CyH/EtOAc 6+1, later 3+1) to obtain product (31) as a light yellow solid (300mg, 57%). [N. Miyaura; A. Suzuki; *Chem. Rev.*; 1995; 95; 2457].  $^1H$  NMR (400MHz,  $CDCl_3$ ): 1.28 (t, 3 H,  $J = 7.1$  Hz); 3.82 (s, 2 H); 4.19 (q, 2 H,  $J = 7.1$  Hz); 6.77-6.84 (m, 2 H); 6.91 (d, 1 H,  $J = 3.5$  Hz); 7.04 (d, 1 H,  $J = 3.5$  Hz); 7.13 (td, 1 H,  $J = 7.8$  Hz, 1.3 Hz); 7.25 (d, 1 H,  $J = 7.8$  Hz).

[0034] Step 4: (The following reaction is done in an anhydrous  $N_2$  atmosphere.) Suspend EDC hydrochloride (86.3mg, 0.45mmol) in anhydrous dichloromethane (1.4mL), add triethylamine (0.063mL, 0.45mmol) and stir for 10min at rt. Add 2-(2,3,4-Trimethoxy-phenyl)-acetic acid (74.7mg, 0.33mmol) and DMAP (3.7mg, 0.03mmol) and stir for 15min. Add ester (31) (64.9mg, 0.30mmol) and stir the reaction solution 22h at rt. Partition the reaction solution between dichloromethane and water (1+1), separate layers and extract aq. layer with dichloromethane (3 times). Wash the combined organic layer with brine and dry with  $Na_2SO_4$ . Purify crude product by preparative radial chromatography (silica gel 60PF, CyH/EtOAc 3+2) to obtain product (32) as yellow oil (118mg, 84%).  $^1H$  NMR (400MHz,  $CDCl_3$ ): 1.29 (t, 3 H,  $J = 7.1$  Hz); 3.58 (s, 2 H); 3.74 (s, 3 H); 3.78 (s, 3 H); 3.79-3.80 (m, 2 H); 3.86 (s, 2 H); 4.20 (q, 2 H,  $J = 7.1$  Hz); 6.58 (d, 1 H,  $J = 8.6$  Hz); 6.59 (d, 1 H,  $J = 3.5$  Hz); 6.75 (d, 1 H,  $J = 3.5$  Hz); 6.85 (d, 1 H,  $J = 8.6$  Hz); 7.05 (t, 1 H,  $J = 7.8$  Hz); 7.26 (dd, 1 H,  $J = 7.8$  Hz, 1.3 Hz); 7.30 (td, 1 H,  $J = 7.8$  Hz, 1.3 Hz); 7.90 (br.s, 1 H); 8.38 (d, 1 H,  $J = 8.3$  Hz).

[0035] Step 5: Dissolve ester (32) (118mg, 0.25mmol) in methanol (8.0mL), add a 1M aq. LiOH solution (1.76mL, 1.76mmol) and stir 20h at rt. Remove solvent under reduced pressure and partition residue between  $CHCl_3$  and 0.5M HCl (1+1). Separate the aqueous layer and extract 3 times with  $CHCl_3$ . Wash the combined organic layer with brine and dry with  $Na_2SO_4$ . Remove solvent under reduced pressure and dry the residue without further purification in oil pump vacuum to obtain crude product (33) as light brown foam (120mg, quant.).  $^1H$  NMR (400MHz,  $CDCl_3$ ): 3.58 (s, 2 H); 3.73 (s, 3 H); 3.78 (s, 3 H); 3.85 (s, 2 H); 3.86 (s, 3 H); 6.58-6.61 (m, 1 H); 6.59 (d, 1 H,  $J = 8.3$  Hz); 6.77 (d, 1 H,  $J = 3.5$  Hz); 6.86 (d, 1 H,  $J = 8.3$  Hz); 7.06 (t, 1 H,  $J = 7.8$  Hz); 7.22-7.27 (m, 1 H); 7.31 (td, 1 H,  $J = 7.8$  Hz, 1.3 Hz); 7.86 (br.s, 1 H); 8.37 (d, 1 H,  $J = 8.3$  Hz).


[0036] Step 6: (The following reaction is done in an anhydrous  $N_2$  atmosphere.) Dissolve (33) (118mg, 0.27mmol) in anhydrous dichloromethane (2.5mL), cool to -78°C (acetone/ dry ice) and add slowly a 1M  $BBr_3$  solution in dichloromethane (1.61mL, 1.61mmol). Stir the reaction mixture for additional 30min at -78°C. Remove cooling bath and stir the reaction mixture for 4h at rt. Cool reaction mixture to 0°C, add slowly water (1.00mL) under vigorous stirring. Partition the reaction mixture between EtOAc and water (1+1). Extract the separated aqueous layer with EtOAc (2 times) and wash the combined organic layer with brine and dry with  $Na_2SO_4$ . Remove solvent under reduced pressure and purify crude product by preparative RP HPLC (gradient, water/ $CH_3CN$  95:5) to obtain (5-[2-[2-(2,3,4-Trihydroxy-phenyl)-acetyl-amino]-phenyl]-thiophen-2-yl) acetic acid (34) as a light brown foam (53mg, 50%).  $^1H$  NMR (400MHz,  $CDCl_3$ ): 3.54 (s, 2 H); 3.82 (s, 2 H); 6.34 (d, 1 H,  $J = 8.3$  Hz); 6.49 (d, 1 H,  $J = 8.3$  Hz); 6.76 (d, 1 H,  $J = 3.3$  Hz); 6.81 (d, 1 H,  $J = 3.3$  Hz); 7.18 (t, 1 H,  $J = 7.6$  Hz); 7.32 (t, 1 H,  $J = 7.8$  Hz); 7.39 (d, 1 H,  $J = 7.3$  Hz); 7.90 (d, 1 H,  $J = 8.1$  Hz); 8.20 (br.s, 1 H).

## EXAMPLE 3

## 4-(3,4,5-Trihydroxy-benzoylamino)-butyric acid (36)

[0037]

SCHEME 8



[0038] Step 1: (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.) Dissolve 4-amino-butyric acid ethyl ester hydrochloride (11) (3.98g, 23.74mmol) in anhydrous dichloromethane (120mL) at rt and add triethylamine (8.30mL, 59.55mmol). Stir the reaction solution for 15min at rt, add portionwise 3,4,5-trimethoxy-benzoyl chloride (6.58g, 28.53mmol) and stir for additional 24h at rt.

Hydrolize the reaction solution with methanol, filtrated the mixture through a short pad of silica gel with EtOAc/CyH (3+1). Purify crude product by flash chromatography (silica gel, EtOAc/CyH 2+1, later 3+1) to obtain (35) as a white solid (4.48g, 58%). <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 1.22 (t, 3 H, J = 7.1Hz); 1.95 (Ψquint, 2 H, J = 6.5Hz); 2.44 (t, 2 H, J = 6.5Hz); 3.48 (td, 2 H, J<sub>1</sub> = 6.5Hz, J<sub>2</sub> = 5.8Hz); 3.85 (s, 3 H); 3.89 (s, 6 H); 4.10 (q, 2 H, J = 7.1Hz); 6.72 (br.s, 1 H); 7.02 (s, 2 H).

[0039] Step 2: Dissolve (35) (4.48g, 13.79mmol) in acetonitile (100mL) at rt and add 1M aqu. LiOH (41.4mL, 41.4mmol). Stir reaction mixture for 18h at rt.


Hydrolize the reaction mixture (cooling bath) with 1M aqu. HCl (50mL). Extract the mixture with chloroform (3 times), wash the combined organic layers with brine and dry with Na<sub>2</sub>SO<sub>4</sub> to obtain 4-(3,4,5-trihydroxy-benzoylamino)-butyric acid (36) as a white solid (4.07g, 99%). No further purification. <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 1.94 (Ψquint, 2 H, J = 6.7Hz); 2.46 (t, 2 H, J = 6.7Hz); 3.50 (br.td, 2 H); 3.85 (s, 3 H); 3.88 (s, 6 H); 6.61 (br.s, 1 H); 7.00 (s, 2 H).

## EXAMPLE 4

## 3-[4-(3,4,5-Trihydroxy-benzoylamino)-butyrylamino]-benzoic acid (38)

{0040}

SCHEME 9



**[0041] Step 1:** (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.) Dissolve EDC x HCl (141mg, 0.74mmol) and Et<sub>3</sub>N (0.105mL, 0.74mmol) in anhydrous DCM (4.0mL) and stir for 5min at rt. Added (36) (208mg, 0.70mmol) and DMAP (8.6mg, 0.07mmol) and stir for 5min. Add 3-Aminomethyl-benzoate (159mg, 1.05mmol) and stir the reaction solution for 21h at rt. Hydrolyze the reaction solution with sat. aqu NH<sub>4</sub>Cl and water, separate layers, extract aqu layer with EtOAc (3 times) and wash the combined organic layer with water and brine and dry with Na<sub>2</sub>SO<sub>4</sub>. Purified crude product by flash chromatography (silica gel 60, EtOAc/CyH 3+1, later EtOAc/MeOH 9+1) to obtain (37) as a white solid (219mg, 72%). <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 2.01-2.10 (br.m, 2 H); 2.52 (br.t, 2 H, J ca. 6Hz); 3.55-3.63 (br. m, 2 H); 3.85 (s, 6 H); 3.89 (s, 3 H); 7.02 (s, 2 H); 7.35 (dd, 1 H, J<sub>1</sub> = 8.1Hz, J<sub>2</sub> = 7.6Hz); 7.75 (d, 1 H, J = 7.6Hz); 7.80 (d, 1 H, J = 8.1Hz); 8.15 (s, 1 H); 8.55 (br.s, 1 H).


**[0042] Step 2:** (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.) Dissolve (37) (86mg, 0.2mmol) in anhydrous DCM (4.0mL) at -25°C and add dropwise BBr<sub>3</sub> (0.303mL, 3.20mmol). The reaction mixture is slowly warmed up to rt and stir for additional 6h at rt. Cool reaction mixture to 0°C, add dropwise water/THF (1+1, 1mL) followed by DCM (2mL). Stir overnight and add MeOH (2mL) to homogenize the mixture. Remove solvent under reduced pressure and purify crude product by preparative RP HPLC (gradient, water/MeCN 95:5) to obtain 3-[4-(3,4,5-Trihydroxy-benzoylamino)-butyrylamino]-benzoic acid (38) as a white solid (41mg, 55%). <sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD): 2.02 (br.tt, 2 H, J<sub>1</sub> = 7.1Hz, J<sub>2</sub> ca. 6.5Hz); 2.50 (t, 2 H, J = 7.1Hz); 3.46 (br.t, 2 H, J ca. 6.5Hz); 6.90 (s, 2 H); 7.43 (dd, 1 H, J<sub>1</sub> = 8.1Hz, J<sub>2</sub> = 7.6Hz); 7.78 (d, 1 H, J = 7.6Hz); 7.85 (d, 1 H, J = 8.1Hz); 8.26 (br.s, 1 H).

## EXAMPLE 5

4-[[4-(2,3,4-Trihydroxy-benzoylamino)-butyrylamino]-methyl]-cyclohexanecarboxylic acid (46)

[0043]

## SCHEME 10



[0044] Step 1: Dissolve 4-Aminomethyl-cyclohexanecarboxylic acid ((39); 1.15g, 7.30mmol) in 1,4-dioxane (12.0mL) and 10% aq. Na<sub>2</sub>CO<sub>3</sub> (23.2mL) and add Fmoc-Cl (2.26g, 8.76mmol). Stir the reaction mixture for 2.5h at rt. Add 1M aq. HCl (42.0mL) to the mixture and extract with EtOAc (3 times). Wash the combined organic layers with 1M aq. HCl, water and brine, extract the combined aq. layers once again with EtOAc, dry the combined organic layers with Na<sub>2</sub>SO<sub>4</sub> and remove solvent under reduced pressure. The left crude product is washed with ice cold EtOAc and dried in oil pump vacuum to obtain (40) as a white solid (2.28g, 83%). No further purification. [M. Nichifor; E. H. Schacht; *Tetrahedron*; 1994; 50; 12; 3747-3760]. <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): 0.87-1.02 (br.m, 2 H); 1.34-1.52 (br.m, 4 H); 1.81 (br.d, 2 H, J = 6Hz); 1.90-2.11 (br.s, 1 H); 2.12-2.35 (br.m, 1 H); 3.03 (Ψt, 2 H, J = 6.2Hz); 4.19 (br.Ψt, 1 H, J = 6.5Hz); 4.42 (br.Ψd, 2 H, J = 6.5Hz); 4.74 (br.s, 1 H); 7.30 (Ψt, 2 H, J = 7.4Hz); 7.38 (Ψt, 2 H, J = 7.4Hz); 7.57 (d, 2 H, J = 7.4Hz); 7.75 (d, 2 H, J = 7.4Hz).

[0045] Step 2: Dissolve (40) (190mg, 0.5mmol) in DCM (0.5mL) and DMF (0.25mL) at rt in a pre-dried tube, add DIEA (0.52mL, 1.5mmol) and add this solution to 2-chlorotriethylchlorid-polystyrene (82mg, 0.13mmol) which is preswollen before in DCM (0.15mL). Shake the reaction suspensions for 14h at rt. The resin is (41) washed with DCM/MeOH/DIEA (17+2+1, 3 times). DCM (once), DMF (3 times) and again DCM (twice) and dried in vacuum. [i.e. Novabiochem® 2000 Catalog; 2000; S15-S18].

[0046] Step 3: Suspend complete amount of resin (41) from step 2 in DMF (0.4mL) and piperidine (0.1mL) and shake it for 1.5h at rt. Washed resin (42) with DMF (3 times) and DCM (3 times for 30min) and dry in vacuum.

[0047] Step 4: Complete amount of resin (42) from step 3 was preswollen in DMF (0.8mL) for 20min. Dissolve acid (43) (175mg, 0.59mmol) and HOBt (90mg, 0.59mmol) in DMF (2.8mL) at rt, add DIC (75mg, 0.59mmol), stir for 15min and add this solution to the preswollen resin (42). Shake the resin suspension gently for 20h at rt. Wash resin (44) with DMF (3 times) and DCM (4 times) and dry in vacuum.

[0048] Step 5: Suspend complete amount of resin (44) in 1.5mL of DCM+HFIP (2+1) and shake for 45min at rt. Filter the remaining solution of and wash resin once with DCM. Repeat cleavage procedure and washing once. Evaporate solvent of the combined filtrates under reduced pressure to afford crude product (45). No further purification.

[0049] Step 6: (The following reaction is done in an anhydrous N<sub>2</sub> atmosphere.) Suspend complete amount of crude (45) from step 3 in anhydrous DCM (2.0mL), cooled it to -40°C and added BBr<sub>3</sub> (0.15mL, 1.59mmol). Shake the reaction suspension for 1h at -40°C, 2h at -25°C and 30min at +5°C. Add dropwise water under vigorous stirring followed by MeOH. Remove solvent under reduced pressure. Purify the crude product by preparative R<sub>F</sub>:PLC (gradient, water/MeCN 95:5) to obtain (46) (9mg, 17% over 5 steps) as a beige solid. <sup>1</sup>H NMR (400MHz, CD<sub>3</sub>OD): 1.02 (d, 2H, J<sub>1</sub> = 3.0Hz, J<sub>2</sub> = 12.3Hz); 1.30-1.55 (m, 3H); 1.86 (br.d, 2H, J = 13Hz); 1.94 (q, 2H, J = 7.1Hz); 2.03 (br.d, 2H, J = 13Hz); 2.24 (q, 1H, J<sub>1</sub> = 3.3Hz, J<sub>2</sub> = 12.3Hz); 2.31 (t, 2H, J = 7.1Hz); 3.05 (d, 2H, J = 6.6Hz); 3.43 (t, 2H, J = 7.1Hz); 6.40 (d, 1H, J = 8.8Hz); 7.16 (d, 1H, J = 8.8Hz).

#### Sialyl Lewis<sup>x</sup> Tyrosine Sulfate Assay (sLe<sup>x</sup> TSA):


[0050] Compounds of the present invention are assayed on a molecular level for their ability to inhibit the binding of P-, L-, or E-selectin chimeric molecules to sLe and tyrosinesulfate residues linked to a polymeric matrix as a PSGL-1 substitute. Selected 50% inhibitory concentrations (IC<sub>50</sub>-values) are determined.

Microtiter plates are coated overnight in carbonate buffer pH9.6 with goat anti human Fc mAB (10 µg/ml). After washing in assay buffer (25mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 150mM NaCl, 1mM CaCl<sub>2</sub> pH7.4) and blocking (3% bovine serum albumin (BSA) in assay buffer) plates are incubated for 2h at 37°C with human P-Selectin-IgG-chimera (0.61nM respectively 150ng/mL) or human L-Selectin-IgG-chimera (0.61nM respectively 131ng/mL). 5µl of sLe<sup>x</sup>-tyrosine sulfate polyacrylamide (1mg/ml) carrying 15% sLe<sup>x</sup>, 10% Tyrosine-sulfate and 5% biotin is complexed with 20µl Streptavidin-Peroxidase solution (1mg/ml) and 25µl assay buffer without CaCl<sub>2</sub>. For use in the assay, the ligand complex is diluted 1:10000 in assay buffer and further diluted 1:1 with varying amounts of compounds in assay buffer incl. 2%DMSO. This mixture is added to the wells precoated with P- or E-selectin. After incubation for 2h at 37°C, wells are washed for six times with in assay buffer incl. 0.005% Polyoxyethylenesorbitan monolaurate (TWEEN 20), developed for 10-15min with 20µl 3,3',5,5'-tetramethylbenzidine (TMB)/H<sub>2</sub>O<sub>2</sub> substrate solution and stopped with 20µl 1M H<sub>2</sub>SO<sub>4</sub>. Bound sLe<sup>x</sup>-Tyrosine sulfate ligand complex is determined by measuring optical density at 450nm vs. 620nm in a Fusion alpha-FP reader (sold from Packard Bioscience, Dreieich, Germany).

[0051] The compounds referred to in the following SCHEME11 are those compounds referred to as the particularly preferred compounds herein.



## SCHEME 11



EP 1 577 289 A1

Table of sLe <sup>x</sup> TSA Data; <i>in vitro</i> Inhibition of E-/P-/L-Selectin at 100 $\mu$ M						
Compound	E-Selectin [% inhib.]	STD	P-Selectin [% Inhib.]	STD	L-Selectin [% inhib.]	STD
34	46.5	4.4	92.4	0.2	81.9	0.6
47	56.2	9.4	97.4	0.4	87.7	4.2
48	79.4	1.7	78.2	2.7	76.2	1.6
49	54.4	10.0	84.9	1.4	88.4	2.5
50	89.2	0.4	90.5	1.0	81.7	0.5
51	63.1	9.4	86.2	2.2	73.7	2.8
52	32.9	7.0	87.4	0.2	81.0	1.6
53	58.5	1.4	57.7	4.3	52.3	3.8
54	58.9	4.3	96.5	1.0	83.6	1.0
55	37.6	4.1	51.2	1.3	48.7	7.0
56	50.4	1.8	93.1	0.9	95.2	0.5
57	99.8	2.1	97.9	0.4	96.5	0.2
58	68.9	5.0	87.3	0.7	81.7	0.9
59	67.5	2.3	67.1	8.4	62.4	3.4
60	90.2	4.0	86.3	2.2	84.9	1.9
61	52	0.6	94.6	2.5	85.4	4.7
62	53.4	7.6	87.2	0.7	75.4	1.0
63	85.4	5.3	86.6	1.6	84	2.2
64	82.9	1.4	73.1	1.4	72.6	2.8
65	96.4	3.3	96.1	0.6	92	1.0
66	46	6.9	99.1	0.1	97.4	0.3
67	38.7	4.0	97.7	0.2	83.8	1.2
68	42.2	5.6	73.8	3.1	48.8	3.1
69	38.7	9.1	99.2	0.1	95.0	0.4
70	n.a.		89.4	2.1	88.7	3.6
71	92.7	2.8	88.6	1.9	87.4	1.5
72	94.9	5.1	86.6	3.7	89.9	3.9
73	53.5	0.7	79.4	2.8	66.2	3.2

Results from sLe <sup>x</sup> TSA: IC <sub>50</sub> Data for E-/ P-/ L-Selectin						
Compound	IC <sub>50</sub> E-Selectin [ $\mu$ M]	STD	IC <sub>50</sub> P-Selectin [ $\mu$ M]	STD	IC <sub>50</sub> L-Selectin [ $\mu$ M]	STD
34	n.a.		7.7	1.0	11.6	3.3
51	0.8	0.2	1.1	0.0	1.4	0.3
53	1.0	0.7	2.1	0.6	n.a.	
57	3.3	2.0	2.4	0.7	3.1	1.0
59	3.0	1.2	2.8	1.1	3.3	0.9

(continued)

**Results from sLe<sup>x</sup>TSA: IC<sub>50</sub> Data for E-/ P-/ L-Selectin**

Compound	IC <sub>50</sub> E-Selectin [ $\mu$ M]	STD	IC <sub>50</sub> P-Selectin [ $\mu$ M]	STD	IC <sub>50</sub> L-Selectin [ $\mu$ M]	STD
60	3.1	2.4	3.4	2.1	5.7	1.0
63	1.3	0.3	1.7	0.5	1.8	0.2
64	2.3	1.0	2.3	0.6	2.3	0.7
66	0.6	0.2	2.1	0.7	7.0	7.7
70	n.a.		7.4	1.0	16.0	4.8
71	7.3	9.4	13.0	17.2	15.0	20.0
72	8.4	5.6	21.7	25.7	109.4	198.8
73	12.2	16.0	14.8	13.9	26.2	32.5

**Flow Chamber Assay / Cell Adhesion and Rolling under Flow Conditions**


**[0052]** To assess the capability of compounds to inhibit cell binding under dynamic conditions resembling the flow in a blood vessel, flow chamber assays addressing/ testing binding of HL-60 cells / various cell lines to P-selectin, L-selectin and E-selectin chimeric molecules are performed.

Cell attachment under flow conditions are determined using a parallel flow chamber system. A 35mm polystyrene culture dish is coated for 1 hour at room temperature with coating buffer (50mM tris-(hydroxymethyl) aminomethane buffer (Tris), 150 mM NaCl, 2 mM CaCl<sub>2</sub>; pH 7,4) containing human E- or P-selectin-IgG chimera at concentrations of 2,5 $\mu$ g/ml or 10 $\mu$ g/ml, respectively. After removal of the coating solution non specific binding sites are blocked for an additional hour with 1% BSA in coating buffer at room temperature. After washing with assay buffer ("Roswell Park Memorial Institute 1640" (RPMI 1640) + 10mM HEPES) the dish is fitted into a parallel plate laminar flow chamber (sold from Glycotech, Rockville, MD) and mounted on an inverted phase-contrast microscope (sold from Olympus, Hamburg, Germany) equipped with a CCD camera (JVC) that is connected to a PC. Employing a peristaltic pump (sold from Ismatec, Wertheim-Mondfeld, Germany) the re-circulating system is equilibrated with assay buffer containing 125 $\mu$ M compound or vehicle control (DMSO). Cells (1 million / ml) are added to the chamber and allowed to distribute for 2 minutes at a high flow rate. The flow rate is then decreased resulting in a calculated flow shear of 1 dyne/cm<sup>2</sup>. Video sequences of 10 low power fields are digitally recorded after 5 minutes continuous flow. The percentage of inhibition is calculated from the mean number of cells per field that attached to the coated dish surface in the presence versus absence of compound of at independent experiments.

Data from Flow Chamber Assay for E- and P-Selectin		
Compound	E-Selectin [% inhib.]	P-Selectin [% inhib.]
57	35	11
63	n.a.	17
71	22	22

**Claims**

1. Compounds having the general structure of formula (I),



wherein the symbols, indices and substituents have the following meaning



if  $R^2=OH$  and  $R^3=H$  then  $R^1=H, CN, NO_2, CF_3, F, Cl, Br, I, CH_3$  or

if  $R^3=OH$  and  $R^2=H$  then  $R^1=H, CN, NO_2, CF_3, F, Cl, Br, I, CH_3, Et, n-Pr, i-Pr, n-Bu, i-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl$  or

if  $R^3=OH$  and  $R^1=H$  then  $R^2=H, CN, NO_2, CF_3, F, Cl, Br, I, CH_3, Et, n-Pr, i-Pr, n-Bu, t-Bu, phenyl, thienyl, furyl, thiazolyl$




-X=

(a)








with -E- being  $-NH-$ ,  $-(CH_2)_kNH-$ ; -G- being  $-(NH)_m$  and  $g = 0, 1$ ;  $h = 1, 2, 3$ ;  $k = 1, 2, 3$ ;  $m = 0, 1$ ;  $n =$  an integer from 1 to 8

(b)




with  $R^4$  being  $H, CH_3, CH_2CH_3$

(c)






with  $R^5$  being H,  $\text{NO}_2$ ,  $\text{CF}_3$ , F, Cl, Br, I, CN,  $\text{CH}_3$  and -K- being -S- or -O-

(d)






with p being an integer from 2 to 8

(e)











with  $q$  being an integer from 1 to 9 and  $r$  being an integer from 1 to 3

(f)



with -T<sup>1</sup>-, -T<sup>2</sup>-being -E-, -K- or -(N-alkyl)-

 $\cdot Y =$






with -V- being -(NH)<sub>s</sub>- with s being 0 or 1,

50 R<sup>6</sup> being CO<sub>2</sub>H, CO<sub>2</sub>Alkyl, CO<sub>2</sub>Aryl, CO<sub>2</sub>NH<sub>2</sub>, CO<sub>2</sub>Aralkyl, SO<sub>3</sub>H, SO<sub>2</sub>NH<sub>2</sub>, PO(OH)<sub>2</sub>, 1-H-tetrazolyl-, CHO, COCH<sub>3</sub>, CH<sub>2</sub>OH, NH<sub>2</sub>, NHAlkyl, N(Alkyl)Alkyl', OCH<sub>3</sub>, CH<sub>2</sub>OCH<sub>3</sub>, SH  
 R<sup>7</sup> independently from R<sup>6</sup> being H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, NO<sub>2</sub> and  
 R<sup>8</sup> independently from R<sup>6</sup> and R<sup>7</sup> being H, CH<sub>3</sub>, CH<sub>2</sub>CH<sub>3</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, NO<sub>2</sub>, R<sup>6</sup>  
 R<sup>9</sup> being H, NO<sub>2</sub>, CF<sub>3</sub>, F, Cl, Br, I, CN, CH<sub>3</sub>, OCH<sub>3</sub>, SH

55 t being 0,1,2

and -W- = -(CH<sub>2</sub>)<sub>v</sub>, *cis*-CH=CH- or *trans*-CH=CH-, and v being 0,1,2

-Z =





(both enantiomers, each)


-W-R<sup>6</sup>

and the pharmaceutically acceptable salts, esters or amides and prodrugs of the above identified compounds of formula (I).


2. Compounds according to claim 1, wherein the compounds are defined by formulas (A) and (B)



wherein -Y is (Q=CH, N)










with  $R^{10}$  being  $CO_2H$ ,  $CO_2alkyl$ ,  $CO_2aryl$ ,  $CO_2NH_2$ ,  $CO_2aralkyl$ ,  $CH_2SO_3H$ ,  $CH_2SO_2NH_2$ ,  $CH_2PO(OH)_2$ , 1-H-tetrazolyl,  $CHO$ ,  $COCH_3$ ,  $CH_2OH$ ,  $CH_2NH_2$ ,  $CH_2NHalkyl$ ,  $CH_2N(alkyl)alkyl'$ ,  $CH_2OCH_3$ ,  $CH_2SH$ ,  $R^{11}$  being  $CO_2H$ ,  $CO_2alkyl$ ,  $CO_2aryl$ ,  $CO_2NH_2$ ,  $CO_2aralkyl$ ,  $SO_3H$ ,  $SO_2NH_2$ ,  $PO(OH)_2$ , 1-H-tetrazolyl,  $CHO$ ,  $COCH_3$ ,  $OH$ ,  $NH_2$ ,  $NHalkyl$ ,  $N(alkyl)alkyl'$ ,  $OCH_3$ ,  $SH$ .

3. Compounds according to claim 1, wherein the compounds are defined by formulas (C) and (D)



wherein Y is like relating to formulas (A) and (B) and X is:



4. Pharmaceutical compositions comprising at least one compound of the formula (I) and a pharmaceutically acceptable carrier which is useful in a medicine.
5. Pharmaceutical compositions according to claim 4, comprising at least one compound of formula (A) or formula (B) or formula (C) or formula (D).
6. Method of inhibiting the binding of P-selectin, L-selectin or E-selectin to  $sLe^x$  or  $sLe^a$  and tyrosinesulfate residues comprising the step of administering to a patient an effective amount of at least one compound having the structure of formula (I).
7. Use of compounds according to any one of claims 1 to 3 for the preparation of a medicine for the treatment of a patient, inhibiting the binding of P-selectin, L-selectin or E-selectin to  $sLe^x$  or  $sLe^a$  and tyrosinesulfate residues.



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 04 00 6461  
shall be considered, for the purposes of subsequent  
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	US 6 340 700 B1 (AUGUET MICHEL ET AL) 22 January 2002 (2002-01-22)	1,4-7	C07C233/00 C07C237/00
Y	*columns 1 and 2; the claims and compound with rn 214124-47-7: benzamide, N-[2-(4-aminophenylethyl)-3,4,5-trihydroxy *	2,3	
X	----- DATABASE BEILSTEIN [Online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002296238 retrieved from Xfire accession no. BRN2765383 * abstract *	1,4	
X	----- DATABASE BEILSTEIN [Online] BEILSTEIN INSTITUTE FOR ORGANIC CHEMISTRY, FRANKFURT-MAIN, DE; XP002296239 retrieved from Xfire accession no. BRN2763456 * abstract *	1,4	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C07C
<b>INCOMPLETE SEARCH</b> The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims. Claims searched completely : Claims searched incompletely : Claims not searched : Reason for the limitation of the search: see sheet C			
Place of search Munich		Date of completion of the search 15 September 2004	Examiner Lorenzo Varela, M.J.
<b>CATEGORY OF CITED DOCUMENTS</b> X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			

5  
EPC FORM 1503 03.02 (F04C07)



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 04 00 6461

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	WO 99/29705 A2 (GLYCOMED INCORPORATED, USA; SANKYO CO., LTD.) 17 June 1999 (1999-06-17)	1,4-7	
Y	*the abstract; the examples; the claims and in particular compound 4-piperidinecarboxylic acid, 1-(3,4,5-trihydroxybenzoyl), rn:227462-58-0*	2,3	
X	----- DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NOMOTO, TAKASHI ET AL: "Preparation of hydroxybenzamide derivatives as prevention and treatment agents for bone diseases" XP002296240 retrieved from STN Database accession no. 1996:513596 * abstract * & JP 08 143525 A2 (BANYU PHARMA CO LTD, JAPAN) 4 June 1996 (1996-06-04)	1,4	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	----- DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NAKAJO, KYOSHI ET AL: "Silver halide color photographic material" XP002296241 retrieved from STN Database accession no. 1990:45554 * abstract * & JP 01 120554 A2 (FUJI PHOTO FILM CO., LTD., JAPAN) 12 May 1989 (1989-05-12)	1,4	
	----- -/--		

5

EPO FORM 1503 03.82 (P4/C10)



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 04 00 6461

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SAKAGAMI, MEGUMI: "Silver halide color photographic material" XP002296242 retrieved from STN Database accession no. 1987:467992 * abstract * & JP 61 282839 A2 (FUJII PHOTO FILM CO., LTD., JAPAN) 13 December 1986 (1986-12-13) -----	1,4	
X	US 4 476 219 A (KEI, SAKANOU ET AL) 9 October 1984 (1984-10-09) Benzoic acid, 4-chloro-3-[(3,4,5-trihydroxybenzoyl)amino]-dodecyl ester, rn: 89946-84-9. -----	1,4	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; PASHCHENKO, E. N. ET AL: "Photometric determination of molybdenum in tungsten and its alloys as a carboxygallanilide complex" XP002296243 retrieved from STN Database accession no. 1976:536659 * abstract * & ZHURNAL ANALITICHESKOI KHIMII, 31(2), 400-1 CODEN: ZAKHA8; ISSN: 0044-4502, 1976, ----- -/-	1,4	

5  
EPO FORM 1503 (3.12) (P04C10)



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 04 00 6461

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MAL'TSEV, V. F. ET AL: "Photometric determination of molybdenum" XP002296244 retrieved from STN Database accession no. 1975:612201 * abstract * & SU 480 000 T (USSR) 5 August 1975 (1975-08-05) -----	1,4	
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MORLYAN, N. M. ET AL: "N-(3,4,5-Trimethoxybenzoyl)-p-aminobenzoic acid" XP002296245 retrieved from STN Database accession no. 1972:85515 * abstract * & METODY POLUCH. KHIM. REAKTIV. PREP., NO. 20, 121-3 FROM: REF. ZH., KHIM. 1971, ABSTR. NO. 2ZH230, 1969, -----	1,4	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SLYUSARE, A. T. ET AL: "Dissociation of p-carboxygallic anilide" XP002296246 retrieved from STN Database accession no. 1964:428806 * abstract * & UCH. ZAP., KHAR'KOVSK. GOS. UNIV. 133, TR. KHIM. FAK. I NAUCHN.-ISSLED. INST. KHIM., 133(19), 95-103, 1963, ----- -/--	1,4	

EPO FORM 1513 03/82 (P04C10)

European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 04 00 6461

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; LAPIN, N. N. ET AL: "Determination of titanium in heat-resistant steels" XP002296247 retrieved from STN Database accession no. 1964:86480 * abstract * & SB. NAUCHN. TR. ZHDANOVSK. MET. INST. , (9), 103-7 FROM: REF. ZH., KHIM. 1963, ABSTR. NO. 20G101., 1963, -----	1,3	
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SLYUSAREV, A. T. ET AL: "Dissociation of p-carboxygallanilide" XP002296248 retrieved from STN Database accession no. 1962:446636 * abstract * & UKRAINSKII KHIMICHESKII ZHURNAL (RUSSIAN EDITION) , 28, 309-15 CODEN: UKZHAI; ISSN: 0041-6045, 1962, -----	1,4	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MANNING, D. L. ET AL: "Association constants of silver(I) and cyanide ions in molten equimolar sodium nitrate-potassium nitrate mixtures" XP002296249 retrieved from STN Database accession no. 1962:446635 * abstract * & INORG. CHEM. , 1, 594-9, 1962, ----- -/--	1,4	

5  
EPO FORM 1500 (03.02) (P04C10)



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number  
EP 04 00 6461

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SHINGAKI, TADAO: "Reaction of substituted benzazides with benzylamine" XP002296250 retrieved from STN Database accession no. 1961:22545 * abstract * & NIPPON KAGAKU ZASSHI , 80, 55-8 CODEN: NPKZAZ; ISSN: 0369-5387, 1959, -----	1,4	
X	DATABASE CHEMABS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SLYUSAREV, A. T. ET AL: "Gallic acid anilides" XP002296251 retrieved from STN Database accession no. 1961:22544 * abstract * & UKRAINS'KII KHEMICHNII ZHURNAL , 26, 364-7 CODEN: UKHZAS; ISSN: 0372-4190, 1960, -----	1,4	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
Y	WO 2004/018502 A1 (YAMANOUCHI EUROPE B.V., NETH.) 4 March 2004 (2004-03-04) *the whole document; in particular, table 3*	1-7	
Y	WO 97/01569 A (CIBA GEIGY AG ; KOLB HARTMUTH C (DE)) 16 January 1997 (1997-01-16) 3-piperidinol,5-[[3-0-[(1S)-1-carboxy-2-cyclohexylethyl]-.beta.-D-galactopyranosyl]oxy]-4-[(6-deoxy.alpha.-L-galactopyranosyl)oxy]-1-(3,4,5-trihydroxybenzoyl)-monosodium salt, (3R,4R,5R) and its use. ----- -/--	1-7	

5  
EPO FORM 1505 (03.02) (P04C10)



European Patent  
Office

## PARTIAL EUROPEAN SEARCH REPORT

Application Number

EP 04 00 6461

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
Y	EP 1 081 151 A (EISAI CO LTD ; MERCIAN CORP (JP)) 7 March 2001 (2001-03-07) * the whole document *	1-7	
Y	WO 03/075905 A (LOPEZ-BELMONTE PASCUAL JUAN ; BOBEL 246 S L (ES); LOPEZ-BELMONTE PASCU) 18 September 2003 (2003-09-18) * the whole document *	1-7	
Y	APPELD00RN, CHANTAL C. M. ET AL: "Rational Optimization of a Short Human P-selectin -binding Peptide Leads to Nanomolar Affinity Antagonists" JOURNAL OF BIOLOGICAL CHEMISTRY , 278(12), 10201-10207 CODEN: JBCHA3; ISSN: 0021-9258, 2003, XP002296281 *the whole document; in particular, table 11*	1-7	
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

5  
EPO FORM 1503 03.02 (PULC10)



European Patent  
OfficeINCOMPLETE SEARCH  
SHEET CApplication Number  
EP 04 00 6461

Although claim 6 is directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition in the same extent as explained herein below for the compound claims 1-3.

-----

Claim(s) searched incompletely:  
1-7

Reason for the limitation of the search:

Present claims 1-7 relate to an extremely large number of possible compounds/compositions and their use in medicine. Support within the meaning of Article 84 EPC and disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds claimed (those ones in the activity examples). In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds disclosed in the activity examples. In fact, the claims contain so many options, variables, possible permutations and different possibilities of attachment of the different options that a lack of clarity within the meaning of Article 84 EPC arises to such an extent as to render a meaningful search of the claims impossible. Consequently, as explained above, the search has been carried out for those parts of the application which do appear to be clear, namely the compounds in the activity examples and closely related homologous compounds; compounds according to formulae A, B wherein Y is as in claim 2 with R10 and R11 being C02H or C02alkyl.

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 04 00 6461

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDF file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15-09-2004

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 6340700	B1	22-01-2002	FR 2761066 A1	25-09-1998
			AT 241612 T	15-06-2003
			AU 733173 B2	10-05-2001
			AU 6404398 A	20-10-1998
			BR 9808427 A	23-05-2000
			CA 2285037 A1	01-10-1998
			CN 1143854 C	31-03-2004
			DE 69815094 D1	03-07-2003
			DE 69815094 T2	05-02-2004
			DK 973763 T3	29-09-2003
			EP 0973763 A1	26-01-2000
			ES 2200318 T3	01-03-2004
			WO 9842696 A1	01-10-1998
			HU 0001438 A2	28-05-2001
			JP 2001518114 T	09-10-2001
			NO 994620 A	10-11-1999
			NZ 338016 A	28-01-2000
			PL 335838 A1	22-05-2000
			PT 973763 T	31-10-2003
			RU 2183211 C2	10-06-2002
			SK 129899 A3	16-05-2000
			TR 9902382 T2	21-06-2000
			US 2003078420 A1	24-04-2003
			US 6335445 B1	01-01-2002
			US 2002007062 A1	17-01-2002
			US 2002045753 A1	18-04-2002
			US 2002042511 A1	11-04-2002
			ZA 9802203 A	16-09-1998
WO 9929705	A2	17-06-1999	AU 1804299 A	28-06-1999
JP 8143525	A2	04-06-1996	JP 8143525 A	04-06-1996
JP 1120554	A2	12-05-1989	JP 1120554 A	12-05-1989
JP 61282839	A2	13-12-1986	JP 61282839 A	13-12-1986
US 4476219	A	09-10-1984	JP 1036933 B	03-08-1989
			JP 1550196 C	23-03-1990
			JP 58156932 A	19-09-1983
			DE 3308723 A1	22-09-1983
			GB 2117526 A ,B	12-10-1983
SU 480000	T		NONE	
WO 2004018502	A1	04-03-2004	NONE	

EPC-FCRM P2339

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.

EP 04 00 6461

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office ECP file or.  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15-09-2004

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9701569	A	16-01-1997	AU 707474 B2	08-07-1999
			AU 6305396 A	30-01-1997
			BR 9609285 A	11-05-1999
			CA 2224346 A1	16-01-1997
			CN 1196731 A	21-10-1998
			CZ 9704197 A3	17-06-1998
			EA 1356 B1	26-02-2001
			WO 9701569 A1	16-01-1997
			EP 0836610 A1	22-04-1998
			HU 9801805 A2	28-12-1998
			JP 11508548 T	27-07-1999
			NO 976065 A	17-02-1998
			NZ 311686 A	28-01-2000
			PL 324258 A1	11-05-1998
			SI 9620099 A	31-08-1998
			SK 177897 A3	05-08-1998
			TR 9701728 T1	21-03-1998
EP 1081151	A	07-03-2001	AU 3538699 A	06-12-1999
			EP 1081151 A1	07-03-2001
			US 6645996 B1	11-11-2003
			WO 9960000 A1	25-11-1999
WO 03075905	A	18-09-2003	WO 03075905 A1	18-09-2003

EPO FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82